🇺🇸 valsartan/amlodipine in United States
87 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 87
Most-reported reactions
- Hypertension — 19 reports (21.84%)
- Blood Pressure Increased — 15 reports (17.24%)
- Drug Ineffective — 11 reports (12.64%)
- Fatigue — 8 reports (9.2%)
- Malaise — 8 reports (9.2%)
- Hypotension — 6 reports (6.9%)
- Drug Interaction — 5 reports (5.75%)
- Dyspnoea — 5 reports (5.75%)
- Headache — 5 reports (5.75%)
- Oedema Peripheral — 5 reports (5.75%)
valsartan/amlodipine in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Cardiovascular approved in United States
Frequently asked questions
Is valsartan/amlodipine approved in United States?
valsartan/amlodipine does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for valsartan/amlodipine in United States?
Novartis is the originator. The local marketing authorisation holder may differ — check the official source linked above.